Skip to main content
. 2020 Sep 18;14:3803–3813. doi: 10.2147/DDDT.S272442

Table 2.

Primary Endpoints Employed in 145 Included Trials

Category Number of Trials Percentage of Total
Clinical Improvement time or rate 43 29.7%
Virus negative conversion rate or time 27 18.6%
All-cause mortality 21 14.5%
Clinical recovery time or rate 16 11.0%
Adverse outcome 13 9.0%
COVID-19 infection rate 9 6.2%
Inflammatory marker 5 3.4%
Hospitalization or ICU or death 5 3.4%
Oxygen saturation 4 2.8%
Inhospital time 2 1.4%